Skip to main content
. 2024 Feb 15;13(2):465–473. doi: 10.1007/s40120-024-00586-w

Table 4.

Characteristics of patients who experienced side effects on combined therapy (CGRP mAbs and gepants)

Age/gender Class of migraine CGRP mAb Gepants Side effect
Patient X 22/female Episodic Erenumab then switched to eptinezumab Rimegepant Peri-labial numbness and cough
Patient Y 42/female Chronic Erenumab Rimegepant Nausea and vomiting
Patient Z 55/female Chronic Erenumab Rimegepant Constipation